Ibrutinib – LuciBru

What it treats:

Ibrutinib, sold under the brand name Imbruvica, is an oral, small-molecule Bruton’s tyrosine kinase (BTK) inhibitor used primarily for the treatment of several B-cell malignancies and chronic graft-versus-host disease (cGVHD).

Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL):

For adults with CLL/SLL, with or without 17p deletion, as first-line or relapsed/refractory treatment.

Mantle Cell Lymphoma (MCL): For adults with MCL who have received at least one prior therapy (accelerated approval based on response rate).

Waldenström’s Macroglobulinemia (WM): For adults with WM, as monotherapy or in combination with rituximab.

Marginal Zone Lymphoma (MZL): For adults with MZL who require systemic therapy and have received at least one prior anti-CD20-based therapy (accelerated approval).

Chronic Graft-Versus-Host Disease (cGVHD): For adults with cGVHD after failure of one or more prior systemic therapies (e.g., corticosteroids).